News
Pomerantz LLP is investigating claims on behalf of investors of Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO). Such investors are advised to contact Danielle Peyton ...
Novo Nordisk has struggled to adapt to very high demand and a market where celebrities are more influential than doctors.
COPENHAGEN (Reuters) -Shares in Wegovy maker Novo Nordisk fell further on Wednesday as analysts warned of persistent ...
Kumar now believes the stock is only worthy of a hold recommendation, down from his previous assessment of buy. He also significantly lowered his price target, chopping it to 360 Danish krone ($55.49) ...
Some of the most recognizable brand names that could be impacted by new tariffs include Ozempic and Wegovy, two injectable drugs that have grown popular in recent years for their abilities to ...
Furious competition in GLP-1 drugs rebuts the anti-pharma crowd.
We recently published 12 Stocks Jim Cramer Recently Discussed As He Commented On A “Sea Of Green”. ABC is one of the stocks Jim Cramer recently discussed. Novo Nordisk A/S (NYSE:NVO), the Danish ...
The fast-selling GLP-1 drug matched Lilly's older medicine Trulicity in a closely watched cardiovascular outcomes trial, while showing greater weight loss and blood sugar control.
While Eli Lilly’s diabetes blockbuster was non-inferior to its older incretin therapy Trulicity in a highly anticipated Phase III cardiovascular outcomes trial, analysts had hoped for statistical ...
Ozempic-famed Novo Nordisk took over a $70 billion wipeout off its market value this week. Is this the beginning of a trend, ...
In a market note, the investment firm said it downgraded Novo Nordisk A/S (NYSE:NVO) to “neutral” from “buy” previously and ...
Eli Lilly (LLY) stock in focus as its diabetes drug Mounjaro causes heart benefits suceeding in a late-stage trial versus its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results